Hepatocellular carcinoma (HCC) has become an important public health problem, and there are still challenges to overcome in clinical treatment. The nanodrug delivery system (NDDS) has developed tremendously in recent years, and many researchers have explored NDDS for the treatment of HCC. Engineered cell membrane-coated nanoparticles (ECNPs) have emerged, combining the unique functions of cell membranes with the engineering versatility of synthetic nanoparticles (NPs) to effectively deliver therapeutic drugs. It is designed to have the capabilities: specific active targeting, immune evasion, prolonging the circulation blood time, controlled drug release delivery, and reducing drugs systematic toxicity. Thus, ECNPs are a promising bionic tool in the treatment of HCC and have operability to achieve combination and integrated therapy. This review focuses on the mechanism and strategy of ECNPs for the treatment of HCC and summarizes its research progress in the treatment of HCC in recent years.

1.
Today C
, Estimated number of incident cases and deaths World, both sexes, all ages, 2023. 2023.
2.
3.
A.
Villanueva
,
New Eng. J. Med.
380
,
1450
(
2019
).
4.
S.
Abbina
,
E.
Siren
,
H.
Moon
, and
J. N.
Kizhakkedathu
,
ACS Biomater. Sci. Eng.
4
,
3658
(
2018
).
5.
X.
Chi
,
K.
Liu
,
X.
Luo
,
Z.
Yin
,
H.
Lin
, and
J.
Gao
,
J. Mater. Chem. B
8
,
3747
(
2020
).
6.
C. M.
Hu
,
L.
Zhang
,
S.
Aryal
,
C.
Cheung
,
R. H.
Fang
, and
L.
Zhang
,
Proc. Natl. Acad. Sci. U.S.A.
108
,
10980
(
2011
).
7.
J. A.
Copp
et al,
Proc. Natl. Acad. Sci. U.S.A.
111
,
13481
(
2014
).
8.
10.
R.
Bazak
,
M.
Houri
,
S. E.
Achy
,
W.
Hussein
, and
T.
Refaat
,
Mol. Clin. Oncol.
2
,
904
(
2014
).
11.
S.
Wang
,
P.
Huang
, and
X.
Chen
,
Adv. Mater.
28
,
7340
(
2016
).
12.
N.
Gupta
,
D. B.
Rai
,
A. K.
Jangid
, and
H.
Kulhari
,
Curr. Drug Metab.
20
,
506
(
2019
).
14.
15.
J.
Winkler
,
A.
Abisoye-Ogunniyan
,
K. J.
Metcalf
, and
Z.
Werb
,
Nat. Commun.
11
,
5120
(
2020
).
16.
C. Y.
Zhang
,
X.
Dong
,
J.
Gao
,
W.
Lin
,
Z.
Liu
, and
Z.
Wang
,
Sci. Adv.
5
,
eaax7964
(
2019
).
17.
Z.
Zhang
et al,
Int. Immunopharmacol.
99
,
107624
(
2021
).
18.
H.
Wang
et al,
J. Nanobiotechnol.
17
,
60
(
2019
).
20.
L. J.
Gay
and
B.
Felding-Habermann
,
Nat. Rev. Cancer
11
,
123
(
2011
).
21.
L.
Xu
,
S.
Wu
, and
X.
Zhou
,
J. Biomater. Appl.
33
,
72
(
2018
).
22.
L.
Wu
et al,
J. Mater. Chem. B
8
,
4648
(
2020
).
23.
R. J.
Bose
,
R.
Paulmurugan
,
J.
Moon
,
S. H.
Lee
, and
H.
Park
,
Drug Discov. Today
23
,
891
(
2018
).
24.
J. C.
Harris
,
M. A.
Scully
, and
E. S.
Day
,
Cancers
11
,
1836
(
2019
).
26.
M.
Espinoza
,
K. S.
Lin
,
M. T.
Weng
,
S. C.
Kunene
,
Y. S.
Lin
, and
Y. T.
Lin
,
Int. J. Biol. Macromol.
228
,
487
(
2023
).
27.
28.
E. J.
Comparetti
,
P.
Lins
,
J.
Quitiba
, and
V.
Zucolotto
,
J. Biomed. Mater. Res. A
110
,
1499
(
2022
).
32.
M.
Li
,
W.
Zhang
,
B.
Wang
,
Y.
Gao
,
Z.
Song
, and
Q. C.
Zheng
,
Int. J. Nanomed.
11
,
5645
(
2016
).
34.
Y.
Wang
,
X.
Chen
,
D.
He
,
Y.
Zhou
, and
L.
Qin
,
Mol. Pharm.
15
,
5728
(
2018
).
35.
36.
S. A.
Grupp
et al,
New Eng. J. Med.
368
,
1509
(
2013
).
40.
Z.
Li
,
G.
Yang
,
L.
Han
,
R.
Wang
,
C.
Gong
, and
Y.
Yuan
,
J. Nanobiotechnol.
19
,
360
(
2021
).
42.
43.
Y.
Sun
et al,
J. Nanobiotechnol.
18
,
60
(
2020
).
44.
J.
Liu
et al,
ACS Appl. Mater. Interfaces
15
,
6260
(
2023
).
46.
J.
Lehár
et al,
Nat. Biotechnol.
27
,
659
(
2009
).
48.
M. J.
Jeon
et al,
J. Exp. Clin. Cancer Res.
33
,
57
(
2014
).
49.
D. E.
Dolmans
,
D.
Fukumura
, and
R. K.
Jain
,
Nat. Rev. Cancer
3
,
380
(
2003
).
50.
M.
Shams
,
B.
Owczarczak
,
P.
Manderscheid-Kern
,
D. A.
Bellnier
, and
S. O.
Gollnick
,
Cancer Immunol. Immunother.
64
,
287
(
2015
).
51.
C.
Jiang
,
H.
Cheng
,
A.
Yuan
,
X.
Tang
,
J.
Wu
, and
Y.
Hu
,
Acta Biomater.
14
,
61
(
2015
).
52.
54.
X.
Huang
,
H.
Guo
,
L.
Wang
, and
Z.
Shao
,
Biomater. Transl.
3
,
201
(
2022
).
55.
X.
Liu
et al,
Acta Physiol.
213
,
505
(
2015
).
56.
Q.
Yang
et al,
Bioeng. Transl. Med.
8
,
e10559
(
2023
).
You do not currently have access to this content.